Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update

Posted by Brenda Bartman on Jul 11th, 2026

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Get Free Report) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 67,330 shares, a growth of 759.2% from the June 15th total of 7,836 shares. Currently, 3.4% of the shares of the stock are sold short. Based on an average trading volume of 399,320 shares, the short-interest ratio is currently 0.2 days.

Biodexa Pharmaceuticals Trading Down 3.9%

Shares of NASDAQ BDRX traded down $0.10 during midday trading on Friday, reaching $2.49. The company had a trading volume of 16,657 shares, compared to its average volume of 224,157. Biodexa Pharmaceuticals has a one year low of $2.40 and a one year high of $66.50. The firm’s fifty day moving average price is $3.22 and its 200-day moving average price is $5.61.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

A hedge fund recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC acquired a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals accounts for 0.6% of Sabby Management LLC’s holdings, making the stock its 10th largest holding. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 17.51% of the company’s stock.

Analyst Ratings Changes

BDRX has been the topic of a number of recent analyst reports. Weiss Ratings raised shares of Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. Wall Street Zen cut shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 30th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

View Our Latest Research Report on BDRX

About Biodexa Pharmaceuticals

(Get Free Report)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.